Ketryx, a provider of agentic continuous compliance platforms for safety-critical product development, announced today that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. Hawkins also participated in the company’s Series B financing, signaling strong industry confidence in Ketryx’s mission to transform compliance in life sciences.
Hawkins, who led Medtronic from 2007 to 2011, brings decades of experience in medical device innovation and regulatory strategy. His appointment comes as Ketryx addresses a critical bottleneck in the industry: integrating artificial intelligence into safety-critical product development while maintaining rigorous compliance with regulatory standards.
Ketryx’s platform helps companies in medical devices, pharmaceuticals, and robotics accelerate product development by automatically generating compliant documentation, maintaining continuous traceability, and enabling safe and verifiable AI at scale. The platform overlays existing tools to reduce manual work by up to 90 percent, according to the company.
“Ketryx is solving one of the most pressing challenges in life sciences: how to leverage AI without compromising safety or regulatory compliance,” said Hawkins. “I look forward to helping the company scale its impact.”
The company’s agentic continuous compliance platform is already trusted by four of the world’s top five medical device manufacturers. By automating documentation and traceability, Ketryx helps teams identify and close compliance gaps, improving both speed and quality across the product lifecycle.
The news matters because the life sciences industry is under increasing pressure to innovate faster, particularly with the rise of AI-driven diagnostics, personalized medicine, and connected devices. However, regulatory hurdles often slow down development. Ketryx’s approach aims to remove that bottleneck without requiring companies to overhaul their existing workflows.
For more information, visit www.ketryx.com.
